髓源性免疫抑制细胞表达与肝动脉化疗栓塞术后肝衰竭的关系分析

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (1351 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the relationship between the occurrence of hepatic failure after transcatheter arterial chemoembolization(TACE)and the expression of myeloid-derived suppressor cell(MDSC).Methods Altogether 237 patients with HBV-related primary liver cancer(PLC)who were hospitalized in our hospital from May 2011 to January 2015 were selected as the subject of this research,according to the the occurrence of liver failure,all patients were divided into 105 cases in liver failure group and 132 cases in non-liver failure group.The difference of MDSC expressions after TACE was analyzed.According to the degree of liver failure,all the patients were divided into mild liver failure group(47 cases),moderate group(31 cases),severe group(27 cases),according to the prognosis of liver failure,all the patients were divided into death group(10 cases)and improvement group(95 cases).The difference of MDSC expressions in each group was compared.Results The MDSC-m phenotype of the PLC patients in liver failure group was significantly higher than that in the non-liver failure group,with significant difference(P=0.0405).MDSC-m of severe liver failure group was significantly higher than that of mild group,with significant difference between the two groups(P＜0.001).MDSC-m level of the liver failure death group was significantly higher than that of improvement group,with significant difference between the two groups(P＜0.01).Conclusion The occurrence and prognosis of hepatic failure after TACE is closely related to the high expression of MDSC.

Key words： Liver cancer Transcatheter arterial chemoembolization Myeloid-derived suppressor cell

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Wei
	SHAO Ming-liang
	LIU Wen-zong
	ZHANG Hai-cong
	YAN Hui-min
	ZHENG Huan-wei

Cite this article:

ZHANG Wei,SHAO Ming-liang,LIU Wen-zong, et al. Analysis of the relationship between expression of myeloid-derived suppressor cell and liver failure after transcatheter arterial chemoembolization[J]. 中国当代医药, 2018, 25(10): 9-12.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I10/9

[3]	国家卫生和计划生育委员会.原发性肝癌诊疗规范（2017年版）[J].临床肝胆病杂志，2017，33（8）：1419-1431.
[5]	汪增秀，谭善忠，孙薇薇，等.外周血T淋巴细胞对乙肝病毒相关慢加急性肝衰竭患者预后的影响[J].安徽医药，2017，21（12）：2173-2176.
[6]	朱雪莲，邓小燕，吴晓蔓，等.髓系来源性抑制细胞在HBV感染相关性肝癌中的表达及意义[J].实用医学杂志，2017，33（13）：2226-2228.
[1]	Mark WR，Cathal H，Cliona OF，et al.Liver immunology and its role in inflammation and homeostasis[J].Cell Mol Immunol，2016，13（3）：267-276.
[2]	PanCQ，DuanZ，DaiE.TenofovirtopreventhepatitisBtransmission in mothers with high viral load[J].N Engl J Med， 2016，374（24）：2324-2334.
[8]	Zheng SJ，Qu F，Li JF.Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection[J].Int J Infect Dis，2015，2015：149-155.
[9]	姜枫，杨大明，徐克成.乙型肝炎病毒相关性肝细胞癌抗病毒治疗的研究进展[J].国际消化病杂志，2015，35（1）：12-16.
[13]	揭方荣，鲁晓擘.HBV相关慢加急性肝衰竭的细胞分子免疫机制研究进展[J].传染病信息，2017，30（2）：114-117.
[15]	张巍，闫丹丹，高莉，等.嵌合抗原受体T细胞治疗原发性肿瘤的优势与研究进展[J].天津医药，2016，44（2）：253-255.
[4]	Vinit K，Sima P，Evgenii T，et al.The nature of myeloid-derived suppressor cell in the tumor microen-vironment[J].Trends Immunol，2016，37（3）：208-220.
[7]	Chen LY，Yang B，Zhou L.Promotion of mitochondrial energy metabolism during hepatocyte apoptosis in a rat model of acute liver failure[J].Mol Med Rep，2015，2（4）：5035-5041.
[10]	Atsushi H，Daiju S，Fumie I.Invariant NKT cells are resistant to circulating CD15＋myeloid-derived suppressor cells in patients with head and neck cancer[J].Cancer Sci，2016，107（3）：207-216.
[11]	Dufait I，Van Valckenborgh E，Menu E，et al.Signal transducer and activator of transcription 3 in myeloid-dirived suppressor cell：an opportunity for cancer therapy[J].Oncotarget，2016，7（27）：42698-42715.
[12]	Tuettenberg A，Steinbrink K，Schuppan D.Myeloid cells as orchestrators of the tumor microen vironment：novel targets for nanoparticular cancer therapy[J].Nanomedicine （Lond.），2016，11（20）：2735-2751.
[14]	Yang F，Wei Y，Cai Z，et al.Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3 tumor cells to mediate MDSC chemoattraction via Fas singnaling[J].Cell Mol Immunol，2015，12（1）：66-76.
[16]	安晓刚，张旭，马玉，等.血清甲胎蛋白对HBV相关慢加急性肝衰竭患者的预后分析[J].宁夏医学杂志，2017，39（10）：900-901.
[17]	Wang T，Liu M，Zheng SJ，et al.Tumor-associated autoantiboduies are useful biomarkers in immuno-diagnosis of fetoprotein-negative hepatocellular carcinoma[J].World J Gastroenterol，2017，23（19）：3496-3504.
[18]	孟雪飞，李红兵.髓源抑制细胞对慢性丙型肝炎患者干扰素联合利巴韦林抗病毒治疗临床预后的影响[J].胃肠病学和肝病学杂志，2017，26（3）：307-310.
[19]	龚学艳，胡泰洪，关文锋，等.免疫调节治疗在慢加急性肝衰竭早期患者中应用的临床研究[J].中国中西医结合消化杂志，2017，25（5）：372-375.
[20]	Li JF，Zheng SJ，Wang LL，et al.Glucosylceramide synthase regulates the proliferation and apoptosis of liver cells in vitro by Bcl2/Bax pathway[J].Mol Med Rep，2017，16（5）：7355-7360.